PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial

PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial

Abstract Here we report results of a phase 1 multi-institutional, open-label, dose-escalation trial (NCT02744287) of BPX-601, an investigational autologous PSCA-directed GoCAR-T® cell product containing an inducible MyD88/CD40 ON-switch responsive to the activating dimerizer rimiducid, in patients w...

Full description

Saved in:
Bibliographic Details
Main Authors: Mark N. Stein, Ecaterina E. Dumbrava, Benjamin A. Teply, Usama S. Gergis, Martin E. Guiterrez, Ran Reshef, Sumit K. Subudhi, Céline F. Jacquemont, Joseph H. Senesac, J. Henri Bayle, Charity D. Scripture, Monica S. Chatwal, Mehmet A. Bilen, Walter M. Stadler, Carlos R. Becerra
Format: Article
Language:English
Published: Nature Portfolio 2024-12-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-024-53220-6
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41467-024-53220-6

Similar Items